Compare Davita Inc (DVA) vs GE Aerospace (GE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs GE Aerospace — how do they compare? Davita Inc trades at $232 (market cap $14.92B), while GE Aerospace trades at $354.99 (market cap $369.06B). The key difference: GE Aerospace is far larger — about 24.7× Davita Inc's market cap, and GE Aerospace pays a 0.53% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | GE | |
|---|---|---|
Market Cap | $14.92B | $369.06B |
Sector | Health | Industrials |
52-Week High | $235.71 | $378.68 |
52-Week Low | $103.87 | $259.00 |
Enterprise Value | $27.47B | $378.36B |
Dividend Yield | — | 0.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
GE trades at $353.73, down 1.54% today, with a bullish technical signal from moving averages and oversold RSI levels. The company reported strong Q1 2026 earnings of $1.86 per share, beating estimates, supported by robust aerospace demand and defense contract wins. Revenue grew to $45.86 billion in 2025, with net income margins improving to 17.86%. Analysts maintain a bullish consensus with a $397 price target, citing order growth and backlog strength.
Outlook remains positive due to aerospace momentum and strategic investments, but high valuation ratios (P/E 43.9) and debt levels pose risks. The stock offers upside to consensus targets, though investors should monitor execution on growth initiatives and macroeconomic pressures on defense spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →
